OBJECTIVE: To investigate dynamic changes of pathogenically significant factors of tear fluid in type 2 diabetes patients with hemorrhagic proliferative diabetic retinopathy. MATERIAL AND METHODS: A total of 30 patients (30 eyes) with type 2 diabetes mellitus and proliferative diabetic retinopathy complicated by preretinal and vitreous hemorrhages were assessed and treated with recombinant prourokinase (Gemaza). Levels of VEGF A, MCP-1, MMP-2, and MMP-9 in tear fluid were also measured. RESULTS: Intravitreal injections of recombinant prourokinase led to more considerable gain of visual acuity and decrease of vitreous hemorrhage index in the first 24 hours in comparison with other treatment schemes. Changes of VEGF A and MCP-1 tear levels were insignificant. Increase of matrix proteinases activity was mainly due to MMP-9. CONCLUSION: The use of recombinant prourokinase is associated with clinical improvement in patients with hemorrhagic diabetic retinopathy causing no notable changes in tear levels of proangiogenic cytokines and matrix proteinases.
OBJECTIVE: To investigate dynamic changes of pathogenically significant factors of tear fluid in type 2 diabetespatients with hemorrhagic proliferative diabetic retinopathy. MATERIAL AND METHODS: A total of 30 patients (30 eyes) with type 2 diabetes mellitus and proliferative diabetic retinopathy complicated by preretinal and vitreous hemorrhages were assessed and treated with recombinant prourokinase (Gemaza). Levels of VEGF A, MCP-1, MMP-2, and MMP-9 in tear fluid were also measured. RESULTS: Intravitreal injections of recombinant prourokinase led to more considerable gain of visual acuity and decrease of vitreous hemorrhage index in the first 24 hours in comparison with other treatment schemes. Changes of VEGF A and MCP-1 tear levels were insignificant. Increase of matrix proteinases activity was mainly due to MMP-9. CONCLUSION: The use of recombinant prourokinase is associated with clinical improvement in patients with hemorrhagic diabetic retinopathy causing no notable changes in tear levels of proangiogenic cytokines and matrix proteinases.